Advertisement

Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide

      Type 2 diabetes mellitus (T2DM) is a chronic, progressive, metabolic disorder, associated with the development of both microvascular and macrovascular complications. T2DM is closely related to cardiovascular disease, which is the leading cause of death among affected patients.
      • Joseph JJ
      • Deedwania P
      • Acharya T
      • Aguilar D
      • Bhatt DL
      • Chyun DA
      • Di Palo KE
      • Golden SH
      • Sperling LS
      American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension
      Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement From the American Heart Association.
      Overweight or obesity is a common co-morbid condition in patients with T2DM, which leads to greater increase in cardiovascular and all-cause mortality, compared with patients with T2DM who follow a healthier lifestyle.
      • Zhang Y
      • Pan XF
      • Chen J
      • Xia L
      • Cao A
      • Zhang Y
      • Wang J
      • Li H
      • Yang K
      • Guo K
      • He M
      • Pan A.
      Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies.
      However, obesity is an independent risk factor for cardiovascular disease, without requiring the presence of background T2DM.
      • Ortega FB
      • Lavie CJ
      • Blair SN.
      Obesity and cardiovascular disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Joseph JJ
        • Deedwania P
        • Acharya T
        • Aguilar D
        • Bhatt DL
        • Chyun DA
        • Di Palo KE
        • Golden SH
        • Sperling LS
        • American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension
        Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement From the American Heart Association.
        Circulation. 2022; 145: e722-e759
        • Zhang Y
        • Pan XF
        • Chen J
        • Xia L
        • Cao A
        • Zhang Y
        • Wang J
        • Li H
        • Yang K
        • Guo K
        • He M
        • Pan A.
        Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies.
        Diabetologia. 2020; 63: 21-33
        • Ortega FB
        • Lavie CJ
        • Blair SN.
        Obesity and cardiovascular disease.
        Circ Res. 2016; 118: 1752-1770
        • Sattar N
        • McGuire DK
        • Pavo I
        • Weerakkody GJ
        • Nishiyama H
        • Wiese RJ
        • Zoungas S.
        Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
        Nat Med. 2022; 28: 591-598
      1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity [published online June 4, 2022]N Engl J Med doi: 10.1056/NEJMoa2206038.